Liquidia Technologies Overview
- Founded
-
2004
- Status
-
Public
- Employees
-
63
- Stock Symbol
-
LQDA
- Share Price
-
$8.41
- (As of Friday Closing)
Liquidia Technologies General Information
Description
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.
Contact Information
- 419 Davis Drive
- Suite 100
- Morrisville, NC 27560
- United States
Liquidia Technologies Timeline
Liquidia Technologies Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.41 | $8.78 | $3.38 - $8.99 | $556M | 64.7M | 444K | -$0.56 |
Liquidia Technologies Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 378,176 | 337,119 | 205,347 | 67,226 |
| Revenue | 16,936 | 15,935 | 12,853 | 740 |
| EBITDA | (32,572) | (36,120) | (28,238) | (56,147) |
| Net Income | (36,817) | (41,015) | (34,579) | (59,763) |
| Total Assets | 128,922 | 129,198 | 93,729 | 99,532 |
| Total Debt | 4,265 | 24,463 | 16,080 | 17,142 |
Liquidia Technologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Liquidia Technologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Liquidia Technologies Comparisons
Industry
Financing
Details
000000
000000
Liquidia Technologies Competitors (22)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ocular Therapeutix | Formerly VC-backed | Bedford, MA | 000 | 00000 | 000000 - 000 | 00000 |
| 0000000 0000000000 | Corporate Backed or Acquired | Leiden, Netherlands | 000 | 000000&0 | ||
| 0000000 | Private Equity-Backed | Ann Arbor, MI | 00000 | 0000000 0000 | ||
| 000000 | Private Equity-Backed | Wilmington, NC | 0000 | 00.00 | 000000000000 | |
| 000000000 | Formerly VC-backed | Piscataway, NJ | 0000 | 00000 | 000000000 | 00000 |
Liquidia Technologies Patents
Liquidia Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3452031-A1 | Precision controlled load and release particles for post-operative pain | Inactive | 05-May-2016 | 0000000000 | |
| EP-3452031-A4 | Precision controlled load and release particles for post-operative pain | Inactive | 05-May-2016 | 0000000000 | 0 |
| US-20190209538-A1 | Precision controlled load and release particles for post-operative pain | Inactive | 05-May-2016 | 0000000000 | 0 |
| AU-2023201307-A1 | Dry powder treprostinil for the treatment of pulmonary hypertension | Pending | 05-May-2016 | 0000000000 | |
| AU-2017261317-A1 | Dry powder treprostinil for the treatment of pulmonary hypertension | Inactive | 05-May-2016 | A61K31/557 |
Liquidia Technologies Executive Team (30)
Liquidia Technologies Board Members (16)
| Name | Representing | Role | Since |
|---|---|---|---|
| Arthur Kirsch | Self | Board Member | 000 0000 |
| David Johnson | Self | Board Member | 000 0000 |
| Joanna Horobin | Self | Board Member | 000 0000 |
| Katherine Rielly-Gauvin | Liquidia Technologies | Board Member | 000 0000 |
| Raman Singh | Self | Board Member | 000 0000 |
Liquidia Technologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Liquidia Technologies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Liquidia Technologies ESG
Risk Overview
Risk Rating
Updated May, 09, 2023
33.78 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,517
Rank
Percentile
Pharmaceuticals
Industry
00 of 887
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 427
Rank
Percentile
